Bluebird Names COO, Taps Shire Exec To Lead Euro Ops
Cambridge, MA-based Bluebird Bio (NASDAQ: BLUE) has named Susanna High, formerly of Alnylam Pharmaceuticals and Millennium Pharmaceuticals, its chief operating officer. Andrew Obenshain, a veteran of Shire and Genzyme before that, will lead Bluebird’s operations in Europe.
Underwriters and Partners
Xpertise: Watch + Learn
Sponsored · Whitepaper
Monitoring Solutions for Pharma-CRO/CMO Partnerships to Maintain Quality & Timelines
Implementing electronic solutions for risk mitigation
XiltriX
Xconomy Insight · Special Report
How to Jump 5 Unforeseen Hurdles to Biotech Success – Startup Sourcebook
Insights, wisdom, and inspiration on what it takes
Xconomy Insight · Webinar
The New Era of Emerging Therapies Webinar Series
Potential cures and treatments for diseases are on the horizon for a growing number of patients, thanks to recent breakthroughs in CRISPR gene-editing technologies and in cell and gene therapy.
From Our Advertisers
Investment in Wisconsin startups reaches new record total
Tax credits help tech innovators attract capital, fuel growth
Wisconsin Economic Development Corporation